CAUTION: NEST® is an investigational device and limited by federal (United States) law to Investigational Use


NeoSync’s proprietary technology is patent protected.  This website is provided to satisfy the virtual patent marking provisions of various jurisdictions including those described in the America Invents Act under 35 U.S.C. § 287(a).  The reader is hereby placed on notice of NeoSync, Inc.’s rights in the United States Patents listed on this site and associated with the following products. The following list may not be all inclusive of our issued patents and other products not listed here may also be protected by one or more patents.  Additional U.S. and non-U.S. patents pending.

NEST® (NeoSync-EEG Synchronized TMS) patents - US 8475354, US 8888672, US 8888673, US 8961386, US 8480554, US 9015057, US 8465408, US 8585568, US 8870737, US 8926490, US 9272159, US 9308387


NEST® (NeoSync-EEG Synchronized TMS) delivers low energy, alternating magnetic field stimulation in daily 30 minute sessions (5 days/wk) to gently adjust a depressed brain toward a more normal state.  Unique among TMS therapies, synchronized TMS (sTMS) used by NEST® is personalized to a patient’s individual alpha frequency, as measured by a brief electroencephalogram (EEG) recording.  This configuration allows the magnetic field energy to be reduced, providing patient comfort during stimulation.  The lowered energy requirements also allow NEST® to be much smaller and more portable than traditional TMS systems.  

To learn more about the theory behind sTMS technology, please review our recent journal article found at the link below.  


Transcranial Magnetic Stimulation (TMS) is a safe, non-invasive form of brain stimulation that has been used for decades as a research tool for neurologists.  The use of TMS as a new treatment modality of depression and other CNS diseases has recently gained interest in the psychiatry community and beyond, with four devices cleared by the FDA for treating major depression.